Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 multi-arm pharmacotherapy trial for anorexia nervosa
ACTRN12623001019695Phase 2Recruiting
- Sponsor
- Monash University
- Start
- May 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of memantine, brexpiprazole and zinc gluconate in anorexia nervosa (AN) (4 arms), sponsored by Monash University. Primary endpoints: Change in eating disorder symptoms and Change in body mass index. Started May 2024; status: recruiting.
02
Drugs
memantinebrexpiprazolezinc gluconate
03
Conditions
anorexia nervosa (AN)
Beyond the preview
Go deeper on ACTRN12623001019695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001019695.